Vermillion Appoints Dr. Eric Varma to its Board of Directors
News Sep 17, 2013
Vermillion, Inc. has announced the appointment of Eric Varma, M.D. to its board of directors.
"As a partner at Oracle Investment Management, Vermillion's largest shareholder, and a physician, Eric brings significant financial and commercial experience in the life sciences to our board of directors," said Thomas McLain, Vermillion's president and CEO.
McLain continued, "His expertise will help guide the company as it continues to focus on its novel, high-value diagnostic test, OVA1® and improving the care for women with gynecological cancers."
Dr. Varma is currently a partner at Oracle Investment Management, which is a fundamental research driven investment management company that is exclusively focused on the global health care and bioscience industries.
Prior to joining Oracle Investment Management, he worked at Leerink Swann, the Boston Consulting Group, and the Food and Drug Administration.
Dr. Varma received his B.A. from the University of California Berkeley, M.D. from the Albert Einstein College of Medicine, and M.B.A. from the MIT Sloan School of Management.
Blood Test To Determine When It Is Safe To Return To Play After A Sports-related ConcussionNews
A high-sensitive blood test can aid concussed hockey players when it might be safe to return to play. In a study published by the journal Neurology, researchers at Sahlgrenska Academy have identified a superior blood-based biomarker for assessing subtle brain injury.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018